MenB Vaccine Fails to Shield Men Against Gonorrhoea in Major Clinical Trial

Breakthrough Study Challenges Previous Optimism

MenB vaccine offers men no protection – A comprehensive new investigation indicates that the MenB immunisation provides little to no defence against gonorrhoea, contrary to earlier expectations. Researchers have concluded that despite being made available to vulnerable male populations, this particular vaccine does not appear to prevent gonorrhoea infections effectively. The National Health Service began distributing the MenB shot to men who have sex with men during the previous year. This decision followed preliminary research that hinted at potential protective benefits. However, an extensive Australian trial, recently detailed in the prestigious New England Journal of Medicine, revealed virtually no meaningful variation in gonorrhoea rates between vaccinated individuals and those receiving a placebo. According to the UK Health Security Agency, additional domestic investigations are underway to deliver “more robust data” on the matter. Consequently, the agency is not advising any swift modifications to current protocols. Gonorrhoea represents a widespread bacterial condition spread primarily via sexual intercourse. While it frequently produces symptoms such as genital inflammation, discomfort, and abnormal discharge, certain individuals experience no noticeable signs whatsoever. The immunisation, formally designated as the 4CMenB vaccine, was originally developed to safeguard infants against meningitis B. The microorganisms responsible for both illnesses share close biological connections, which initially sparked hopes for cross-protection.

GoGoVax Trial Results Reveal Disappointing Outcomes

Beginning in August 2025, gay and bisexual men engaging in sex with other men gained access to the MenB vaccine across the UK. This rollout followed multiple investigations indicating a thirty-eight percent decrease in gonorrhoea cases among vaccinated recipients. Nevertheless, fresh research conducted by the University of New South Wales in Sydney presents compelling evidence challenging these earlier conclusions. The GoGoVax study tracked five hundred and eighty-seven participants throughout a two-year period. Researchers divided the cohort equally, administering the MenB vaccine to half while the remaining participants received an inert placebo. At the conclusion of the trial, infection rates proved remarkably comparable: two hundred and ninety-one new gonorrhoea cases emerged among vaccinated men, compared to two hundred and eighty-five in the placebo group. The investigation’s lead authors noted that their outcomes align with two separate studies, collectively offering “strong evidence that the MenB vaccine is not effective for gonorrhea prevention.” Dr Mary Ramsay, who serves as director of public health programmes at UKHSA, emphasised the necessity of examining diverse evidence streams. She stated:

Over 30,000 people in England have started this course of vaccination, and this will provide more robust data on vaccine impact and effectiveness. These findings will be published in due course.

Gonorrhoea Rates Remain Concerningly Elevated

Despite recent improvements, gonorrhoea cases continue sitting at unprecedented levels when measured against a decade ago. England witnessed its highest tally of eighty-two thousand five hundred and ninety-two cases in 2022. Although figures subsequently declined to sixty-three thousand nine hundred and forty-three in 2025, these numbers remain twice as high as those recorded in 2015. The European Centre for Disease Prevention and Control identifies men who have sex with men as the most heavily impacted demographic. Dr Odile Harrison, associate professor within the University of Oxford’s Population Health Infectious Disease Epidemiology Unit, characterised the results as “disappointing” yet stressed they should not terminate efforts toward developing an effective immunisation. She explained:

Gonorrhoea remains a major global public health threat, particularly with the continued emergence of antimicrobial resistance, and an effective vaccine remains a high priority.

Taku Mukiwa, head of health programmes at the sexual health charity Terrence Higgins Trust, echoed these sentiments. He suggested that the Joint Committee on Vaccination and Immunisation ought to review the current vaccine programme given the evolving evidence base.

If the evidence has changed, the approach has to change too.

Mukiwa further highlighted that gonorrhoea rates across the UK have reached extraordinary heights, especially within gay and bisexual communities. He noted increasing prevalence of antibiotic-resistant bacterial strains as well.

What we do know for sure is that condoms and regular testing remain the cornerstones for preventing and stopping onward transmission of STIs, and we must continue to work to bring down the stubbornly high rates of STIs in this country.

The findings have prompted renewed discussion about whether the MenB vaccine programme should be adjusted or potentially scaled back until more conclusive data becomes available. Meanwhile, healthcare professionals continue to advocate for comprehensive sexual health strategies that prioritise proven prevention methods alongside ongoing research into future immunisation options.